Mayumi Okuda|Deborah S. Hasin|Mark Olfson|Sharaf S. Khan|Edward V. Nunes|Iván D. Montoya|Shang-Min Liu|Bridget F. Grant|Carlos Blanco
Generalizability of clinical trials for cannabis dependence to community samples???
Columbia University
growing concern results tightly controlled clinical trials may generalize broader community samples assess proportion community dwelling adults cannabis dependence would eligible typical cannabis dependence treatment study applied standard set eligibility criteria commonly used cannabis outcome studies large n43093 representative us adult sample interviewed facetoface national epidemiologic survey alcohol related conditions nesarc approximately 80 community sample adults diagnosis cannabis dependence n133 would excluded participating clinical trials one common eligibility criteria individual study criteria excluded 0 410 community sample legal problems illicit drug use disorders current use fewer 5 jointsweek excluded largest percentage individuals results extend cannabis dependence concerns typical clinical trials likely exclude community dwelling adults disorder results also support notion clinical trials tend recruit highly selective samples rather adults representative typical patients clinical trials carefully evaluate effects eligibility criteria generalizability results even efficacy trials stringent exclusionary criteria could limit representativeness study results